Eledon Pharmaceuticals Inc
ELDN3.340USD
-0.040-1.18%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
200.01MCap. mercado
7.16P/E TTM
Más Datos de Eledon Pharmaceuticals Inc Compañía
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Información de la empresa
Símbolo de cotizaciónELDN
Nombre de la empresaEledon Pharmaceuticals Inc
Fecha de salida a bolsaSep 17, 2014
Director ejecutivoDr. David-Alexandre C. (DA) Gros, M.D.
Número de empleados31
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 17
Dirección19800 Macarthur Blvd.
CiudadIRVINE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92612
Teléfono19492388090
Sitio Webhttps://eledon.com/
Símbolo de cotizaciónELDN
Fecha de salida a bolsaSep 17, 2014
Director ejecutivoDr. David-Alexandre C. (DA) Gros, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. Steven N. Perrin, Ph.D.
Dr. Steven N. Perrin, Ph.D.
President, Chief Scientific Officer, Director
President, Chief Scientific Officer, Director
--
--
Mr. John S. McBride
Mr. John S. McBride
Independent Director
Independent Director
--
--
Mr. Paul Little
Mr. Paul Little
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 4 de jul
Actualizado: vie., 4 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
First Light Asset Management, LLC
3.89%
Sphera Funds Management Ltd.
3.85%
Other
70.25%
Accionistas
Accionistas
Proporción
BVF Partners L.P.
10.51%
RA Capital Management, LP
5.96%
The Vanguard Group, Inc.
5.54%
First Light Asset Management, LLC
3.89%
Sphera Funds Management Ltd.
3.85%
Other
70.25%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
28.61%
Investment Advisor
17.21%
Investment Advisor/Hedge Fund
10.61%
Venture Capital
5.96%
Corporation
1.36%
Research Firm
1.17%
Pension Fund
0.12%
Family Office
0.07%
Individual Investor
0.03%
Other
34.87%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
126
38.97M
65.08%
-2.26M
2025Q1
124
39.32M
65.66%
-3.87M
2024Q4
105
38.47M
64.39%
+11.26M
2024Q3
70
19.89M
51.00%
-1.66M
2024Q2
71
20.04M
55.99%
+4.61M
2024Q1
65
11.37M
47.26%
-1.53M
2023Q4
63
10.93M
50.76%
-2.06M
2023Q3
65
10.70M
50.83%
-4.12M
2023Q2
66
11.20M
53.85%
+179.31K
2023Q1
67
8.42M
61.13%
-3.83M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BVF Partners L.P.
6.29M
10.51%
--
--
Mar 31, 2025
RA Capital Management, LP
3.57M
5.96%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.95M
4.93%
+58.49K
+2.02%
Mar 31, 2025
First Light Asset Management, LLC
2.33M
3.89%
--
--
Mar 31, 2025
Sphera Funds Management Ltd.
2.31M
3.85%
-244.50K
-9.58%
Mar 31, 2025
Blue Owl Capital Holdings LP
1.82M
3.04%
-140.00K
-7.14%
Mar 31, 2025
Woodline Partners LP
1.67M
2.79%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.59M
2.65%
+1.32M
+489.41%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
1.32M
2.2%
-196.91K
-12.99%
Mar 31, 2025
Ensign Peak Advisors, Inc.
1.26M
2.11%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.04%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Inspire Fidelis Multi Factor ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.04%
Global X Russell 2000 ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
ALPS Medical Breakthroughs ETF
Proporción0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Inspire Fidelis Multi Factor ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Fecha
Tipo
Relación
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
Oct 02, 2020
Merger
18<1
